Allogene Therapeutics, Inc.
ALLOHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframePart of the healthcare sector, Allogene Therapeutics, Inc. (ALLO) is listed under Biotechnology. At a $617.8M market cap, Allogene Therapeutics, Inc. ranks as a small-cap company within healthcare. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies.
Market Cap
$617.8M
Beta
0.46
P/E (TTM)
—
P/E (Fwd)
-2.62
EPS (TTM)
$-0.77
EPS (Fwd)
$-0.68
ROE
-52.3%
ROA
-26.0%
Cash
$266.9M
Total Debt
$81.1M
Free CF
-$69.9M
52W Change
43.2%
Annual Financials
Cash vs Debt
Allogene Therapeutics, Inc. holds $266.9M in cash against $81.1M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$69.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -52.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $156K (2022) to $0 (2025), a 100% decline worth watching.
The relatively low beta of 0.46 suggests ALLO is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ALLO.